BridgeBio Pharma (BBIO) Prepaid Assets (2018 - 2026)

BridgeBio Pharma has reported Prepaid Assets for 9 years, with the latest figure at $62.9 million in Q1 2026.

• Quarterly Prepaid Assets rose 77.95% year-over-year to $62.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62.9 million (up 77.95% YoY) and the FY2025 annual result came in at $44.1 million, up 26.39% from the prior year.
• Prepaid Assets grew to $62.9 million in Q1 2026 per BBIO's latest filing, from $44.1 million in the prior quarter.
• Over five years, Prepaid Assets peaked at $62.9 million in Q1 2026 and troughed at $20.5 million in Q2 2023.
• A 5-year average of $34.8 million and a median of $32.8 million in 2022 frame the typical range for Prepaid Assets.
• The sharpest annual moves came in 2023 and 2025: Prepaid Assets slumped 37.27% in 2023, then jumped 112.14% in 2025.
• Over 5 years, Prepaid Assets stood at $21.9 million in 2022, then rose by 10.87% to $24.3 million in 2023, then soared by 43.46% to $34.9 million in 2024, then grew by 26.39% to $44.1 million in 2025, then soared by 42.76% to $62.9 million in 2026.
• According to Business Quant data, Prepaid Assets over the past three periods registered $62.9 million, $44.1 million, and $52.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.